[ad_1]
The Prime Minister signs the acquisition of a vaccine against COVID-19 between the Ministry of Public Health and AstraZeneca. With the goal of administering 26 million doses of the first vaccine by the middle of next year.
Today (27 November 20), Prime Minister General Prayut Chan-o-cha presides over the signing ceremony of the contract to supply the COVID-19 vaccine with prior reservation. And vaccine purchase contracts with AstraZeneca Co., Ltd. amounted to 26 million doses between the Ministry of Public Health and AstraZeneca Company by Dr. Nakorn Premsri, Director of the National Vaccine Institute, MD. Acting on behalf of the Managing Director of the Department of Disease Control, along with Mr. James Teak, President of AstraZeneca (Thailand) Co., Ltd. and Mr. Adrian Kemp, Secretary of the Company. AstraZeneca UK Limited by Mr. Anutin Charnvirakul, Deputy Prime Minister and Minister of Public Health. Witnesses were General Sathitpongsukwimol, Chairman of Siam BioScience Company Limited, Mr. Roongrote Rangsiyopas, Chairman of SCG, and Mr. Alexandra McKenzie, British Ambassador. To Thailand and Mr. Nicholas Weeks, Acting Deputy Ambassador of the Kingdom of Sweden Together with Mr. Phitsanu Suwannachat, Thai Ambassador to London, honored the ceremony.
The prime minister said Thailand has been very successful in curbing the COVID-19 epidemic and is also deeply affected by the economy. Therefore, early access to the COVID-19 vaccine. It is a sustainable solution to combat this epidemic. The Thai government was able to provide the vaccine developed by the universities of Oxford and AstraZeneca. By pre-reserving 26 million doses, it is ensured that Thais will have access to effective and safe vaccines. In addition, the government has continuously supported the progress of vaccine development in the countries of various universities. In addition to the success of vaccine development in various countries, the government is also concerned about cooperation. Give Thais the widest possible access to vaccines
“This is an important opportunity to showcase the international strength of Thailand’s biopharmaceutical industry. Including Thailand’s role as a major vaccine producer in Southeast Asia“Said the prime minister.
Anutin Charnvirakul, Deputy Prime Minister and Minister of Public Health, said from the Ministry of Public Health and Astra Seneca. Have reached an agreement on the supply of vaccines. Developed By Oxford University With AstraZeneca Company Giving Siam Bioscience Co., Ltd. the sole vaccine producer for Thailand and Southeast Asia. The first vaccine is expected to be delivered in mid-2021, and the Cabinet approved on November 17, 2020 to approve the coronavirus vaccination program for 2019 for citizens by prior reservation with the company. AstraZeneca has a cap of 6,049.72 million baht and a budget of 2,379.43 million baht to provide vaccines in advance to 13 million target people to reduce morbidity, mortality and treatment costs. And restore the country’s economy and society to normal conditions. It will also build the potential of the country’s biopharmaceutical industry from the transfer of technology to produce the COVID-19 vaccine.
All this, on November 23, 63 company AstraZeneca announced the preliminary results of the vaccine research that is highly effective in preventing COVID-19 and is highly safe. It can protect vaccinated volunteers from infection. Preliminary analyzes of clinical trials showed that the AZD1222 investigational vaccine had an average effectiveness of 70% and may show up to 90% efficacy, depending on the dose of the concurrent dose. Acceptable among vaccinated subjects and no serious adverse safety events were observed. Furthermore, this vaccine can be stored at temperatures between 2-8 degrees Celsius, making it easy to use and suitable for the Thai healthcare system.
James Teak, President of AstraZeneca (Thailand) Co., Ltd., said AstraZeneca will work with Siam Bioscience Global expansion of AZD1222 vaccine capacity through technology transfer has been in operation since October. And it can be done according to plan. Meanwhile Ministry of Health and AstraZeneca have coordinated together to prepare for the process. Apply for approval for vaccine registrations to be able to operate quickly and meet the highest safety standards under Thailand’s public health regulations.
“AstraZeneca is proud to support the government’s COVID-19 vaccine strategy through the provision of the investigational COVID-19 vaccine AZD1222, developed by the University of Oxford in collaboration with AstraZen. Neka Que will be produced in Thailand At the same time, thank you for your advice and guidance. I believe that this cooperation will be the solution to the problem of this epidemic. Bringing Good Health and More Progress to Thailand”Mr. James said.
[ad_2]
